SG11202005873QA - Fusion protein comprising il-2 protein and cd80 protein, and use thereof - Google Patents

Fusion protein comprising il-2 protein and cd80 protein, and use thereof

Info

Publication number: SG11202005873QA
Authority: SG; Singapore
Prior art keywords: protein; fusion; fusion protein
Prior art date: 2018-09-17

Application number

SG11202005873QA

Inventor

Myung Ho Jang

Original Assignee

Gi Innovation Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-09-17

Filing date

2019-09-16

Publication date

2020-07-29

2019-09-16 Application filed by Gi Innovation Inc filed Critical Gi Innovation Inc

2020-07-29 Publication of SG11202005873QA publication Critical patent/SG11202005873QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Oncology (AREA)
Microbiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG11202005873QA 2018-09-17 2019-09-16 Fusion protein comprising il-2 protein and cd80 protein, and use thereof SG11202005873QA (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
KR20180110698		2018-09-17
KR20190001867		2019-01-07
US201962832013P	2019-04-10	2019-04-10
KR20190053436		2019-05-08
PCT/KR2019/011928 WO2020060122A1 (en)	2018-09-17	2019-09-16	Fusion protein comprising il-2 protein and cd80 protein, and use thereof

Publications (1)

Publication Number	Publication Date
SG11202005873QA true SG11202005873QA (en)	2020-07-29

Family

ID=69887592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202005873QA SG11202005873QA (en)	2018-09-17	2019-09-16	Fusion protein comprising il-2 protein and cd80 protein, and use thereof

Country Status (22)

Country	Link
US (4)	US11492384B2 (en)
EP (2)	EP3715367B1 (en)
JP (2)	JP7085644B2 (en)
KR (2)	KR102201086B1 (en)
CN (2)	CN111971295B (en)
AU (1)	AU2019343850B2 (en)
CA (1)	CA3086486A1 (en)
CL (1)	CL2020001872A1 (en)
DK (1)	DK3715367T3 (en)
ES (1)	ES2985387T3 (en)
FI (1)	FI3715367T3 (en)
HU (1)	HUE068059T2 (en)
IL (1)	IL275592B (en)
MX (1)	MX2020007072A (en)
PE (1)	PE20201418A1 (en)
PH (1)	PH12020551026A1 (en)
PL (1)	PL3715367T3 (en)
PT (1)	PT3715367T (en)
SG (1)	SG11202005873QA (en)
TW (2)	TWI755630B (en)
WO (1)	WO2020060122A1 (en)
ZA (1)	ZA202003645B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7461741B2 (en) *	2016-06-20	2024-04-04	カイマブ・リミテッド	Anti-PD-L1 and IL-2 Cytokines
KR102201086B1 (en) *	2018-09-17	2021-01-11	(주)지아이이노베이션	Fusion protein comprising il-2 protein and cd80 protein and use thereof
EP4063491B1 (en)	2019-11-20	2024-11-13	GI Cell, Inc.	Composition for culturing natural killer cells and method for preparing natural killer cells by using same
BR112022009521A2 (en) *	2019-11-20	2022-08-16	Gi Cell Inc	COMPOSITION OF MEDIUM FOR T-CELL CULTURE AND METHOD FOR T-CELL CULTURE USING THE SAME
US20230014358A1 (en) *	2019-11-27	2023-01-19	Gi Cell, Inc.	Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein
CN114746544A (en) *	2019-11-27	2022-07-12	吉爱希公司	Pharmaceutical composition for treating cancer, comprising fusion protein containing IL-2 protein and CD80 protein and natural killer cells
WO2021187922A1 (en) *	2020-03-18	2021-09-23	(주)지아이이노베이션	Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug
CN115666522B (en)	2020-03-18	2025-05-27	Gi医诺微新	Fusion protein preparation containing IL-2 protein and CD80 protein
US20230139890A1 (en) *	2020-03-18	2023-05-04	Gi Innovation, Inc.	Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereof
KR102545250B1 (en) *	2020-03-31	2023-06-21	한미약품 주식회사	Novel immunostimulating IL-2 analogs
WO2021238904A1 (en) *	2020-05-25	2021-12-02	北京比洋生物技术有限公司	Fc-cd80 fusion protein and conjugate thereof, and use thereof
KR102373965B1 (en)	2020-06-05	2022-03-15	(주)지아이이노베이션	Pharmaceutical composition for enhancing radiotherapy containing fusion protein comprising il-2 protein and cd80 protein
JP2023531876A (en) *	2020-06-30	2023-07-26	ジーアイイノベーション，インコーポレイテッド	Fusion protein comprising anti-LAG-3 antibody and IL-2 and use thereof
MX2022016532A (en) *	2020-07-02	2023-04-12	Inhibrx Inc	Polypeptides comprising modified il-2 polypeptides and uses thereof.
EP4206219A1 (en) *	2020-08-31	2023-07-05	GI Cell, Inc.	Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof
TWI815194B (en)	2020-10-22	2023-09-11	美商基利科學股份有限公司	INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
EP4259648A4 (en) *	2020-12-08	2025-03-26	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS
US20240392004A1 (en) *	2021-03-10	2024-11-28	Immunowake Inc.	Immunomodulatory molecules and uses thereof
WO2022057696A2 (en) *	2021-09-08	2022-03-24	中南大学湘雅医院	Recombinant protein coding sequence, recombinant protein, and method for preparing monoclonal antibodies
WO2023234743A1 (en) *	2022-06-03	2023-12-07	(주)지아이이노베이션	Bispecific antibody including anti-tigit antibody, and use thereof
WO2023249425A1 (en)	2022-06-22	2023-12-28	㈜지아이이노베이션	Fusion protein comprising anti-cd73 antibody and il-2, and use thereof
EP4591873A1 (en) *	2022-09-20	2025-07-30	Gi Biome Inc.	Combined therapy of lactobacillus plantarum strain, and cancer treatment method using same
WO2024063546A1 (en)	2022-09-20	2024-03-28	주식회사 지아이바이옴	Combined therapy of lactobacillus plantarum strain, and cancer treatment method using same
CN115850436A (en) *	2022-10-14	2023-03-28	海徕科(北京)生物技术有限公司	Interleukin 2 mutant and its application
WO2025063755A1 (en) *	2023-09-20	2025-03-27	주식회사 에스엘바이젠	Novel cancer therapeutic agent comprising anticancer dna vaccine and immune response-enhancing fusion protein

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL71275A0 (en) *	1983-03-21	1984-06-29	Sparamedica Ag	Human interleukin-2-and its preparation
CN86104525A (en) *	1985-07-31	1987-02-25	武田药品工业株式会社	The analytical approach of human interleukin-2 and reagent
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en)	1998-05-15	2005-10-18	Bayer Pharmaceuticals Corporation	IL-2 selective agonists and antagonists
DZ2788A1 (en) *	1998-05-15	2003-12-01	Bayer Ag	Selective IL-2 agonists and antagonists.
GB9810999D0 (en)	1998-05-21	1998-07-22	Goken Joop	Materials and methods relating to the expression of genes
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
WO2003015697A2 (en)	2001-08-13	2003-02-27	University Of Southern California	Interleukin-2 mutants with reduced toxicity
DK1454138T3 (en)	2001-12-04	2012-02-13	Merck Patent Gmbh	Immunocytokines with modulated selectivity
CU23229A1 (en)	2002-05-10	2007-09-26	Ct Ingenieria Genetica Biotech	ANTH1 CHEMICAL ANTAGONIST
KR20070003934A (en) *	2004-03-05	2007-01-05	노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드	In vitro test system to predict patient tolerability of therapeutics
ES2417153T5 (en) *	2006-03-06	2024-04-04	Amunix Operating Inc	Unstructured recombinant polymers and uses thereof
JP2009542592A (en)	2006-07-06	2009-12-03	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	Compositions and methods for enhancing the effectiveness of an IL-2-mediated immune response
BRPI0815416A2 (en) *	2007-08-15	2014-10-21	Amunix Inc	COMPOSITIONS AND METHODS FOR MODIFYING PROPERTIES OF BIOLOGICALLY ACTIVE POLYPEPTIDES
CU23923B1 (en)	2010-11-12	2013-07-31	Ct De Inmunología Molecular	POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
ES2694564T3 (en)	2011-02-10	2018-12-21	Roche Glycart Ag	Interleukin-2 mutant polypeptides
EA201892619A1 (en)	2011-04-29	2019-04-30	Роше Гликарт Аг	IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
US8956619B2 (en)	2011-10-25	2015-02-17	University Of Maryland, Baltimore County	Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
US20140377253A1 (en)	2013-03-15	2014-12-25	Abbvie Biotherapeutics Inc.	Fc variants
DK3186283T3 (en)	2014-08-29	2020-03-02	Hoffmann La Roche	Combination therapy with tumor-targeted IL-2 immunocytokine variants and antibodies against human PD-L1
EP3371208B8 (en) *	2015-11-02	2024-10-23	Five Prime Therapeutics, Inc.	Cd80 extracellular domain polypeptides and their use in cancer treatment
CN115073581A (en) *	2016-05-04	2022-09-20	美国安进公司	Interleukin-2 muteins for expansion of T regulatory cells
JP7461741B2 (en) *	2016-06-20	2024-04-04	カイマブ・リミテッド	Anti-PD-L1 and IL-2 Cytokines
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
RU2761377C2 (en)	2017-04-03	2021-12-07	Ф. Хоффманн-Ля Рош Аг	Immunoconjugates of antibody to pd-1 with il-2 or il-15 mutant
KR102201086B1 (en)	2018-09-17	2021-01-11	(주)지아이이노베이션	Fusion protein comprising il-2 protein and cd80 protein and use thereof

2019
- 2019-09-16 KR KR1020190113659A patent/KR102201086B1/en active Active
- 2019-09-16 WO PCT/KR2019/011928 patent/WO2020060122A1/en not_active Ceased
- 2019-09-16 SG SG11202005873QA patent/SG11202005873QA/en unknown
- 2019-09-16 FI FIEP19862449.6T patent/FI3715367T3/en active
- 2019-09-16 CA CA3086486A patent/CA3086486A1/en active Pending
- 2019-09-16 EP EP19862449.6A patent/EP3715367B1/en active Active
- 2019-09-16 PT PT198624496T patent/PT3715367T/en unknown
- 2019-09-16 ES ES19862449T patent/ES2985387T3/en active Active
- 2019-09-16 HU HUE19862449A patent/HUE068059T2/en unknown
- 2019-09-16 PL PL19862449.6T patent/PL3715367T3/en unknown
- 2019-09-16 CN CN201980025699.8A patent/CN111971295B/en active Active
- 2019-09-16 EP EP24175556.0A patent/EP4403635A3/en active Pending
- 2019-09-16 MX MX2020007072A patent/MX2020007072A/en unknown
- 2019-09-16 CN CN202410942368.3A patent/CN118725141A/en active Pending
- 2019-09-16 AU AU2019343850A patent/AU2019343850B2/en active Active
- 2019-09-16 US US16/959,312 patent/US11492384B2/en active Active
- 2019-09-16 DK DK19862449.6T patent/DK3715367T3/en active
- 2019-09-16 PE PE2020000980A patent/PE20201418A1/en unknown
- 2019-09-16 JP JP2020562067A patent/JP7085644B2/en active Active
- 2019-09-17 TW TW108133398A patent/TWI755630B/en active
- 2019-09-17 TW TW110122590A patent/TWI824258B/en active
2020
- 2020-06-17 ZA ZA2020/03645A patent/ZA202003645B/en unknown
- 2020-06-22 IL IL275592A patent/IL275592B/en unknown
- 2020-06-30 PH PH12020551026A patent/PH12020551026A1/en unknown
- 2020-07-14 CL CL2020001872A patent/CL2020001872A1/en unknown
2021
- 2021-01-05 KR KR1020210000775A patent/KR102558191B1/en active Active
2022
- 2022-04-21 JP JP2022070213A patent/JP7569820B2/en active Active
- 2022-08-01 US US17/878,664 patent/US12291555B2/en active Active
- 2022-08-01 US US17/878,703 patent/US12286464B2/en active Active
2025
- 2025-04-01 US US19/097,579 patent/US20250230212A1/en active Pending

Also Published As

Publication number	Publication date
BR112020015030A2 (en)	2021-03-16
CL2020001872A1 (en)	2020-12-18
PH12020551026A1 (en)	2021-09-06
HUE068059T2 (en)	2024-12-28
JP7569820B2 (en)	2024-10-18
TWI755630B (en)	2022-02-21
JP2022115876A (en)	2022-08-09
CA3086486A1 (en)	2020-03-26
US20220389070A1 (en)	2022-12-08
EP4403635A2 (en)	2024-07-24
EP4403635A3 (en)	2024-09-18
AU2019343850A1 (en)	2020-06-25
CN118725141A (en)	2024-10-01
PL3715367T3 (en)	2024-09-02
KR102201086B9 (en)	2022-10-21
MX2020007072A (en)	2020-11-11
KR102201086B1 (en)	2021-01-11
CN111971295A (en)	2020-11-20
JP7085644B2 (en)	2022-06-16
KR20200032009A (en)	2020-03-25
AU2019343850B2 (en)	2024-06-06
US12291555B2 (en)	2025-05-06
EP3715367A4 (en)	2021-05-05
TW202028227A (en)	2020-08-01
PT3715367T (en)	2024-07-25
JP2021511081A (en)	2021-05-06
IL275592A (en)	2020-08-31
IL275592B (en)	2022-02-01
ZA202003645B (en)	2022-09-28
US20200369740A1 (en)	2020-11-26
US11492384B2 (en)	2022-11-08
PE20201418A1 (en)	2020-12-09
US20220380781A1 (en)	2022-12-01
US12286464B2 (en)	2025-04-29
FI3715367T3 (en)	2024-07-23
EP3715367B1 (en)	2024-06-12
US20250230212A1 (en)	2025-07-17
ES2985387T3 (en)	2024-11-05
KR102558191B1 (en)	2023-07-24
EP3715367A1 (en)	2020-09-30
KR20210008110A (en)	2021-01-20
DK3715367T3 (en)	2024-07-29
TWI824258B (en)	2023-12-01
TW202136288A (en)	2021-10-01
CN111971295B (en)	2024-08-02
WO2020060122A1 (en)	2020-03-26

Publication	Publication Date	Title
IL275592B (en)	2022-02-01	Fusion protein comprising il-2 protein and cd80 protein, and use thereof
EP3806889A4 (en)	2022-07-13	Cytokine fusion proteins and uses thereof
EP3623389A4 (en)	2021-01-20	Fusion protein containing tgf- receptor and medicinal uses thereof
EP3737666A4 (en)	2022-01-05	Protein degraders and uses thereof
EP3880814A4 (en)	2022-09-21	Fusion protein
EP3743438A4 (en)	2022-02-23	Cytokine fusion proteins
SG11202012004SA (en)	2021-01-28	Rna-targeting fusion protein compositions and methods for use
EP3147298A4 (en)	2017-12-06	Pd-l1 fusion protein and use thereof
EP3565828B8 (en)	2022-07-27	A sirpalpha-4-1bbl fusion protein and methods of use thereof
ZA202103259B (en)	2022-08-31	Modified cas9 protein, and use thereof
SG11202104912SA (en)	2021-06-29	Fusion protein and use thereof
SG11202110400QA (en)	2021-10-28	Fusion protein and use thereof
EP3831945A4 (en)	2022-05-04	Protein heterodimer and use thereof
EP3836959A4 (en)	2022-05-11	Anti-angiogenesis fusion protein and uses thereof
ZA202000595B (en)	2021-04-28	Novel therapeutic enzyme fusion protein and use thereof
EP3910066A4 (en)	2022-09-07	Dna reference standard and use thereof
EP3849599A4 (en)	2022-06-29	Pneumococcal fusion protein vaccines
IL263842A (en)	2019-01-31	Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
IL279057A (en)	2021-01-31	Endolysin-containing antimicrobial fusion proteins and uses thereof
ZA202102533B (en)	2022-10-26	Fusion protein
IL287601A (en)	2021-12-01	Cd80 variant proteins and uses thereof
EP3101035A4 (en)	2017-07-19	Bifunctional fusion protein, preparation method therefor, and use thereof
EP3856895A4 (en)	2022-08-31	Bihaptenized autologous vaccines and uses thereof
EP3897691A4 (en)	2022-08-31	Il-10-containing vaccines and uses thereof
EP3425054C0 (en)	2023-12-20	Mutant cytochrome protein and use thereof